Aspirin and risk of multiple myeloma in adults: A systematic review and meta-analysis

- This is a systematic review of aspirin use on the incidence risk of multiple myeloma.
- There is no evidence that aspirin modifies the risk of multiple myeloma.
- More studies are needed to assess the impact of aspirin on the risk of multiple myeloma.

Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58−1.39; P=0.638). Odds ratios from the two case-control studies were similar. The findings demonstrated that there was no significant association between aspirin use and the risk of multiple myeloma.